Ena Respiratory

About

Ena Respiratory is a Melbourne-based clinical-stage pharmaceutical company developing antiviral host defense enhancers for respiratory infections.

Mission

Ena Respiratory is a clinical-stage pharmaceutical company focused on combating respiratory viral infections by amplifying the body’s innate immune response. Its lead candidate, INNA-051, is formulated as a convenient once-a-week nasal dry-powder designed to reduce the impact of viral respiratory infections and prevent severe complications in high-risk groups such as the elderly, patients with chronic conditions, and individuals with occupational exposure. The company’s technology centers on locally priming airway mucosa to enhance first-line immune defenses against invading pathogens. Recent financing underscores investor confidence in the potential of INNA-051 as it moves into Phase II clinical trials. With the new funds, Ena Respiratory plans to advance clinical development and generate data that could support broader commercialization or partnership opportunities. Although still pre-revenue, the company’s progress positions it to address significant unmet medical need in antiviral prophylaxis.

Quick Facts